• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

M&A: Alcon Acquires BELKIN Vision for $81M

by Fred Pennic 07/01/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
 M&A: Alcon Acquires BELKIN Vision for $81M

What You Should Know: 

– Alcon (SIX/NYSE: ALC), a company in eye care, announced today the completion of its acquisition of BELKIN Vision for a total of $81M. This strategic move strengthens Alcon’s position in the glaucoma treatment landscape.

– By acquiring BELKIN Vision’s DSLT technology, Alcon expands its treatment options for glaucoma patients. This minimally invasive procedure offers a new tool for physicians, with the potential to improve patient care and outcomes. With planned US market entry and integration into Alcon’s established ecosystem, this acquisition positions Alcon as a leader in providing comprehensive solutions for glaucoma management.

The Deal: Expanding Treatment Options for Glaucoma

The acquisition includes an upfront cash payment of $65M with the potential for an additional $385M based on achieving specific sales milestones. Notably, the deal grants Alcon access to BELKIN Vision’s Direct Selective Laser Trabeculoplasty (DSLT) technology.

DSLT: A Minimally Invasive Treatment for Glaucoma

DSLT is a minimally invasive laser treatment for open-angle glaucoma (OAG) and ocular hypertension (OHT). Clinical studies, including the LiGHT trial and the GLAUrious study, have demonstrated the effectiveness of SLT (Selective Laser Trabeculoplasty) in lowering intraocular pressure (IOP), a key factor in managing glaucoma.

Global Availability and Integration Plans:

Currently, DSLT is approved for use in the European Union (EU) and the United Kingdom (UK). Following the acquisition, Alcon will ensure continued availability in these regions while pursuing FDA clearance for the US market, with a goal of offering the technology to US physicians by the end of 2024.

Integration with Alcon Vision Suite:

Alcon plans to seamlessly integrate DSLT into its Alcon Vision Suite ecosystem. This commitment ensures continued training and best-in-class service for their customers.

“As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, President, Global Surgical Franchise, Alcon. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Healthcare Mergers & Acquisitions

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |